Replimune’s stock spikes as FDA accepts melanoma resubmission, sets April decision date
After rejecting Replimune’s melanoma drug RP1 this summer, the FDA has accepted the biotech’s resubmission of an approval application. The federal agency said it expects to reach a decision on…